Gamma delta HSTCL post allo relapse HLH active disease CD38 positive - Dara refractory options
Reading File
Reading File
Searching PubMed
"hepatosplenic T-cell lymphoma" AND (relapse OR treatment)
Searching PubMed
"gamma delta T-cell lymphoma" AND hemophagocytic
Searching the Web
hepatosplenic T-cell lymphoma relapse after allogeneic transplant treatment options pralatrexate romidepsin ruxolitinib emapalumab HLH
Finding Sources
Searching PubMed
"daratumumab" AND "T-cell lymphoma"
Searching PubMed
"lymphohistiocytosis, hemophagocytic" AND "lymphoma" AND ruxolitinib
Searching PubMed
"hepatosplenic T-cell lymphoma" AND (relapse OR "allogeneic")
Searching PubMed
"hemophagocytic lymphohistiocytosis" AND "meta-analysis" OR "systematic review"
Reading Article
PMID: 42594932
Reading Article
PMID: 42209885
Reading Article
PMID: 38431075
Reading Article
PMID: 40859640
Searching PubMed
"hepatosplenic T-cell lymphoma" AND (STAT5B OR JAK OR "PI3K" OR duvelisib OR pralatrexate)
Searching PubMed
"hemophagocytic lymphohistiocytosis" AND (lymphoma OR malignancy) AND (emapalumab OR "ruxolitinib" OR "doxorubicin" OR "L-DEP")
Searching the Web
relapsed hepatosplenic T-cell lymphoma after allogeneic transplant donor lymphocyte infusion salvage case report ICE alemtuzumab pentostatin
Reading Article
PMID: 41337692
Reading Article
PMID: 38752279
Reading Article
PMID: 40090001
HSTCL (γδ), relapsed after allo-HSCT, with active HLH, CD38+ and daratumumab-refractory
I found no standard of care and no prospective data for this exact situation. Everything below is extrapolated from small series, case reports and HLH data. HLH control comes first, because uncontrolled HLH will usually kill the patient before the lymphoma does.
1. Before choosing a drug
- Re-biopsy (marrow, liver or spleen if safe). Check CD38 level, and check phenotype, because one reported HSTCL with STAT5B and SETD2 mutations relapsed with an NK-cell immunophenotype. Also check CD52, CD30 and CD7, and send NGS for STAT5B, STAT3, PIK3CD and SETD2.
- Chimerism, to confirm host versus donor disease.
- Exclude infectious or post-transplant HLH triggers. These include CMV, EBV, adenovirus and HHV-6, plus TMA and GVHD overlap. Active HLH after allo may not be purely lymphoma-driven.
- Pre-HLH baseline. Record ferritin, sIL-2R, fibrinogen, counts and CXCL9 if available.
2. Controlling the HLH
Cecil says to start treating the malignancy immediately in malignancy-associated HLH, usually with an etoposide-containing regimen plus continued steroids (Goldman-Cecil Medicine, HLH treatment section). Harrison's 22E lists alemtuzumab, emapalumab and ruxolitinib as alternatives, and for transplant-related HLH suggests ruxolitinib, emapalumab and low-dose etoposide as second and third line (Harrison's 22E, HLH treatment and transplant-related HLH sections).
| Option | Evidence | Comment |
|---|---|---|
| Dexamethasone | Backbone for all regimens | Start or continue now. |
| Ruxolitinib | In a phase 2 trial of ruxolitinib plus dexamethasone in newly diagnosed adult HLH, lymphoma-associated HLH had a median OS of only 5.8 months (mostly NK/T-cell lymphoma). | Reasonable bridge. It has some mechanistic rationale because HSTCL is STAT5B/STAT3-driven, but I found no clinical HSTCL data. Watch counts, infection and CMV. One case report in lymphoma-HLH was a cautionary fatal outcome. |
| Emapalumab (anti-IFN-γ) | The REAL-HLH study in malignancy-HLH (n=17) normalised many labs, but 12-month survival was 22%. A small adult salvage series also exists. | Cecil gives 1 mg/kg IV every 3-4 days, titrated up to 10 mg/kg. It does nothing for the lymphoma, so it only buys time. It also carries infection risk. |
| Etoposide (low dose) | Standard for lymphoma-HLH | Hard to use post-allo with poor counts or marrow function. Consider reduced dose or a split schedule. |
| Alemtuzumab | Listed in Harrison's for HLH. An anti-CD52 case of durable survival in αβ HSTCL is cited in the NCI PDQ. | It treats both problems if CD52 is positive, but it brings profound T-cell depletion and high CMV/EBV risk. |
3. Lymphoma-directed options (dara-refractory)
Why not CD38 again. Daratumumab plus GDP was tested in CD38+ relapsed PTCL in a phase 2 FIL study. It closed after 8 patients, with ORR 13%, no CRs, grade 4 thrombocytopenia in 75% and two toxic deaths. I found no data for isatuximab, other CD38 antibodies or CD38 CAR-T in HSTCL. Treat them as unproven. If you are considering them, discuss with the trial network.
Salvage options, mostly case-level evidence:
- ICE or IVAC-type platinum/ifosfamide/cytarabine regimens. HSTCL has historically responded better to these than to CHOP. A case report describes a long CR with lenalidomide-augmented IVAC/ICE followed by allo.
- Pralatrexate. A response was reported in a refractory adolescent (single case).
- Single-agent lenalidomide. A long-term response is reported in an elderly relapsed patient (single case). It is low-toxicity, so it is attractive when counts and HLH limit chemotherapy, but it is anecdotal.
- Other PTCL-class agents are extrapolations only: romidepsin or belinostat, PI3K inhibitors such as duvelisib, and hypomethylating agents. I found no HSTCL-specific evidence. From recall, pentostatin has anecdotal HSTCL activity, but I did not verify this.
- Splenectomy is a reported option for debulking and cytopenias, and may help if hypersplenism is driving transfusion dependence. It is high-risk with active HLH.
Using the graft:
- Taper or stop immunosuppression if there is no significant GVHD.
- DLI is the classic post-allo rescue, but it risks a cytokine surge and GVHD. Give it only after HLH is controlled and ideally after cytoreduction.
- A second allo (haplo or cord) is the only potentially curative route. Cord blood has produced a durable remission in HSTCL with HLH in a single case. This requires reaching a remission or minimal disease first.
- In the EBMT series, allo-HSCT gave 3-year PFS of 50.5% and relapse incidence of 37.9%. I found no good data on outcomes after post-allo relapse.
4. A practical sequence
- Start dexamethasone, then ruxolitinib or emapalumab (or low-dose etoposide if counts allow), and aggressively treat any infection trigger.
- Re-biopsy and re-phenotype in parallel.
- Start lymphoma cytoreduction as soon as HLH is stabilising. Options are a platinum/ifosfamide-based regimen, alemtuzumab if CD52+, or pralatrexate or lenalidomide if the patient is too fragile for chemotherapy.
- Then consolidate with DLI or a second allo if the patient is eligible, or refer for a clinical trial.
Caveats
- Almost all the lymphoma-directed evidence above is single case reports.
- I did not find any recent systematic review that changes this picture.
- The best choice depends on details I don't have: time since transplant, GVHD status, counts, organ function, donor availability, CD52/CD30 status, and which agents the patient has already had. Send those and I can narrow the list.
This is a shared conversation. Sign in to Orris to start your own chat.